Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
Saved in:
| Title: | Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. |
|---|---|
| Authors: | Tsang ES; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Dhawan MS; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Pacaud R; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Thomas S; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Grabowsky J; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Wilch L; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Karipineni S; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Kelley RK; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Ko AH; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Collisson E; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Chapman JS; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Ueda S; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Bergsland EK; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Munster P; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2024 Jun; Vol. 8, pp. e2300494. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38865673 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tsang+ES%22">Tsang ES</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Dhawan+MS%22">Dhawan MS</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Pacaud+R%22">Pacaud R</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Thomas+S%22">Thomas S</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Grabowsky+J%22">Grabowsky J</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Wilch+L%22">Wilch L</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Karipineni+S%22">Karipineni S</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Kelley+RK%22">Kelley RK</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Ko+AH%22">Ko AH</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Collisson+E%22">Collisson E</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Chapman+JS%22">Chapman JS</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Ueda+S%22">Ueda S</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Bergsland+EK%22">Bergsland EK</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Munster+P%22">Munster P</searchLink>; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2024 Jun; Vol. 8, pp. e2300494. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38865673 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/PO.23.00494 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e2300494 Titles: – TitleFull: Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tsang ES – PersonEntity: Name: NameFull: Dhawan MS – PersonEntity: Name: NameFull: Pacaud R – PersonEntity: Name: NameFull: Thomas S – PersonEntity: Name: NameFull: Grabowsky J – PersonEntity: Name: NameFull: Wilch L – PersonEntity: Name: NameFull: Karipineni S – PersonEntity: Name: NameFull: Kelley RK – PersonEntity: Name: NameFull: Ko AH – PersonEntity: Name: NameFull: Collisson E – PersonEntity: Name: NameFull: Chapman JS – PersonEntity: Name: NameFull: Ueda S – PersonEntity: Name: NameFull: Bergsland EK – PersonEntity: Name: NameFull: Munster P IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2473-4284 Numbering: – Type: volume Value: 8 Titles: – TitleFull: JCO precision oncology Type: main |
| ResultId | 1 |